Study to Evaluate CCS1477 (inobrodib) in Haematological Malignancies
NCT04068597
Recruiting
A Phase 1/2a study to assess the safety, tolerability, PK and biological activity of CCS1477 (inobrodib) in patients with Non-Hodgkin Lymphoma, Multiple Myeloma, Acute Myeloid Leukaemia or High Risk Myelodysplastic syndrome.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/05/2025
Locations: The Center for Cancer and Blood Disorders (CCBD), Bethesda, Maryland +15 locations
Conditions: Haematological Malignancy, Acute Myeloid Leukemia, Non Hodgkin Lymphoma, Multiple Myeloma, Higher-risk Myelodysplastic Syndrome, Peripheral T Cell Lymphoma
Register for Updates
Daratumumab, Bortezomib, and Dexamethasone Followed by Daratumumab, Ixazomib, and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma
NCT03763162
Active Not Recruiting
This phase II trial studies how well daratumumab, bortezomib, and dexamethasone followed by daratumumab, ixazomib, and dexamethasone in treating patients with multiple myeloma that has come back (relapsed) or does not response to treatment (refractory). Immunotherapy with monoclonal antibodies, such as daratumumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Drugs used in chemotherapy, such as dexamethasone, work in d... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/05/2025
Locations: M D Anderson Cancer Center, Houston, Texas
Conditions: Recurrent Plasma Cell Myeloma, Refractory Plasma Cell Myeloma
Register for Updates
Cuff Leak Test and Airway Obstruction in Mechanically Ventilated ICU Patients
NCT05456542
Completed
The COSMIC trial will be a multicentred, national, parallel-group, pragmatic vanguard pilot trial.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/05/2025
Locations: The University of Texas Health Science Center at Houston, Houston, Texas +4 locations
Conditions: Respiratory Failure
Register for Updates
UARK 2006-66, Total Therapy 3B: An Extension of UARK 2003-33 Total Therapy
NCT00572169
Active Not Recruiting
With this study - Total Therapy IIIB - researchers are extending the findings of Total Therapy III based what they have learned from the first two studies (Total Therapy I and II), with new research strategies designed to explore why chromosome abnormalities found in persons with multiple myeloma affect the outcome of drug therapy used in this disease."
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/04/2025
Locations: University of Arkansas for Medical Sciences/Myeloma Institute, Little Rock, Arkansas
Conditions: Multiple Myeloma
Register for Updates
Polatuzumab Vedotin With R-GDP in Relapsed/Refractory Diffuse Large B-cell Lymphoma
NCT05498220
Recruiting
This study aimed to evaluate the efficacy of a novel regimen consisting of polatuzumab vedotin in combination with rituximab, gemcitabine, dexamethasone, and cisplatin (PV-RGDP) for the treatment of diffuse large B-cell lymphoma that either came back or did not improve after the treatments (rrDLBCL). This combination has not been approved by the Food and Drug Administration (FDA) for the treatment of rrDLBCL. Salvage therapy (treatment after standard treatment failed) needs to be improved. Ritu... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/04/2025
Locations: Lineberger Comprehensive Cancer Center, Chapel Hill, North Carolina
Conditions: Diffuse Large B-cell Lymphoma
Register for Updates
Study of Chemotherapy-Free Induction Regimen for Ph+ Acute Lymphoblastic Leukemia With Inotuzumab Ozogamicin (InO)
NCT04747912
Recruiting
This research study will add an anti-cancer drug (called inotuzumab ozogamicin also known as "InO") to treatment for participants with newly diagnosed Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia (ALL). Doctors leading this study hope to learn if adding InO to standard induction treatment for Ph+ ALL will lead to quicker, complete molecular remission (where the disease is not detectable even with very sensitive testing techniques). The purpose of this research is to gather... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/04/2025
Locations: University of Chicago Medical Center, Chicago, Illinois
Conditions: Lymphoblastic Leukemia, Acute Lymphoblastic Leukemia, ph+ Acute Lymphoblastic Leukemia
Register for Updates
A Phase II Study of Perioperative Paclitaxel in Patients With Gastric Adenocarcinoma and Carcinomatosis or Positive Cytology
NCT05977998
Recruiting
To learn about the effects of paclitaxel and gastrectomy (surgery to remove all or part of the stomach) on improving outcomes in patients with gastric cancer.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/04/2025
Locations: M D Anderson Cancer Center, Houston, Texas
Conditions: Gastric Adenocarcinoma, Carcinomatosis
Register for Updates
Buprenorphine, Clonidine, and Dexamethasone on Duration of Brachial Plexus Blocks for Upper Extremity Surgery
NCT05824832
Recruiting
The goal of this clinical trial is to learn if there is a difference in morphine requirements in patients after upper extremity surgeries including shoulder arthroscopy. The main question it aims to answer is whether there is a difference between Interscalene brachial plexus blocks with the addition of buprenorphine, dexamethasone, and clonidine and the same block without the adjuvant.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/04/2025
Locations: Loyola University Chicago, Maywood, Illinois
Conditions: Pain, Postoperative
Register for Updates
A Study to Assess Adverse Events and Change in Disease Activity of Intravenously (IV) Infused Etentamig (ABBV-383) in Combination With Anti-Cancer Regimens for the Treatment of Adult Participants With Relapsed/Refractory Multiple Myeloma
NCT05259839
Recruiting
Multiple myeloma (MM) is a plasma cell disease characterized by the growth of clonal plasma cells in the bone marrow. The purpose of this study is to assess the safety and toxicity of etentamig (ABBV-383) when co-administered with pomalidomide-dexamethasone (Pd), lenalidomide-dexamethasone (Rd), or daratumumab-dexamethasone (Dd), in adult participants with relapsed/refractory (R/R) multiple myeloma (MM). Adverse events and change in disease activity will be assessed. Etentamig is an investigati... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/03/2025
Locations: University of Arkansas for Medical Sciences /ID# 243096, Little Rock, Arkansas +48 locations
Conditions: Relapsed/Refractory Multiple Myeloma
Register for Updates
Venetoclax, Daratumumab, and Dexamethasone for Systemic Light-Chain Amyloidosis With Translocation (11;14) (ALTITUDE)
NCT05486481
Withdrawn
This phase I/II trial tests the safety, side effects, and best dose of venetoclax, daratumumab, and dexamethasone for the treatment of systemic light-chain amyloidosis in patients with a deoxyribonucleic acid (DNA) abnormality called a translocation involving chromosomes 11 and 14, or "t(11;14)". Venetoclax works by attaching to a protein called Bcl-2, in order to kill cancer cells. Daratumumab works by binding to a target on the surface of cancer cells called Cluster of differentiation 38 (CD38... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/03/2025
Locations: University of California, San Francisco, San Francisco, California
Conditions: AL Amyloidosis, Light Chain (AL) Amyloidosis, Systemic Light Chain Disease
Register for Updates
Safety and Efficacy Trial of Epcoritamab Combinations in Subjects With B-cell Non-Hodgkin Lymphoma (B-NHL)
NCT04663347
Active Not Recruiting
The purpose of this trial is to measure the safety and effectiveness of epcoritamab (EPKINLY™), either by itself or together with other therapies, when treating participants with B-cell non-Hodgkin Lymphoma (B-NHL). The aim of the first part of the trial is to identify the most appropriate dose of epcoritamab, and the aim of the second part of the trial is to assess the selected epcoritamab dose in a larger group of participants with B-NHL. All participants in this trial will receive either epco... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/03/2025
Locations: University of Alabama at Birmingham, Birmingham, Alabama +57 locations
Conditions: Diffuse Large B-Cell Lymphoma, Follicular Lymphoma
Register for Updates
Postoperative Steroid Use in Adolescent Idiopathic Scoliosis and Neuromuscular Scoliosis Patients
NCT06023043
Not Yet Recruiting
The goal of this randomized clinical trial is to compare the immediate use of steroids after surgery for accelerated discharge in adolescent idiopathic scoliosis and neuromuscular scoliosis after a posterior spinal fusion. The main question it aims to answer are: * What are the effects of using steroids immediately after surgery in decreasing opioid use and helping early mobilization(movement)? * Does post-operative steroid use affect the incidence of wound complications and are there any long... Read More
Gender:
ALL
Ages:
Between 9 years and 18 years
Trial Updated:
03/03/2025
Locations: Children's Hospital Los Angeles, Los Angeles, California
Conditions: Neuromuscular Scoliosis, Adolescent Idiopathic Scoliosis
Register for Updates